basepeptide.com VS.

bulkpeptidesupply.com

Ipamorelin + CJC-1295 — Complementary GH Axis Research Blend This combo pairs Ipamorelin (a selective ghrelin/GHSR-1a agonist) with CJC-1295 (a GHRH analogue, ±DAC). Together they’re used to study pituitary growth-hormone (GH) pulsatility, hypothalamic–pituitary regulation, and downstream IGF-1 biology in controlled research settings. Component A — Ipamorelin CAS: 170851-70-4  PubChem CID: 9831659  Sequence (pentapeptide): Aib-His-D-2-Nal-D-Phe-Lys-NH2  Notes: Highly selective for GH release with minimal ACTH/cortisol or prolactin effects vs older GHRPs.  Component B — CJC-1295 (GHRH analogue) Forms: CJC-1295 with DAC (albumin-binding “Drug Affinity Complex”) and CJC-1295 no DAC / Mod GRF(1-29). CAS (reported): with DAC 446262-90-4 ; no-DAC listings vary by substitution, commonly 446036-97-1 or 863288-34-0.  Mechanism: Agonist at the GHRH receptor (GHRHR) on pituitary somatotrophs. PK note: DAC prolongs half-life via albumin binding; no-DAC behaves like short-acting GHRH(1-29) analogues. Why Use the Combo (Plain English) Two switches, one output: CJC-1295 triggers the pituitary via GHRH, while Ipamorelin stimulates the ghrelin/GHSR pathway. Hitting both can amplify GH pulses vs either alone (synergy shown with GHRH + GHRPs/ghrelin).  Clean signal: Ipamorelin is noted for selective GH release with low cortisol/prolactin cross-activation in studies—helpful for tidy readouts.  Design flexibility: Choose no-DAC (short-acting pulses) or DAC (sustained exposure) to match your protocol window. Key Study Themes — What’s Typically Tested GHRH + GHS synergy on GH pulsatility What’s tested: Co-administration of a GHRH analogue with a ghrelin mimetic; serial GH sampling and deconvolution analysis. What changes: Greater peak GH and area-under-curve vs either agent alone in human and animal models.  Why it matters: Models how dual hypothalamic inputs coordinate pituitary output, informing endocrine physiology and test paradigms.  Selectivity &am